JP2002104965A - Composition having function of prophylaxis and amelioration of fatty liver - Google Patents

Abstract

PROBLEM TO BE SOLVED: To obtain a new oil and fat composition having functions of prophylaxis and amelioration of fatty liver and a food and a medicine using the same. SOLUTION: This oil and fat composition comprises at least one or more of conjugated highly unsaturated fatty acids having a conjugated triene structure in the molecule, salts thereof and ester derivatives thereof and has functions of the prophylaxis and amelioration of the fatty liver. The food and medicine use the oil and fat composition.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

[0001] The present invention relates to a compound represented by the formula-(CH
= CH-CH = CH-CH = CH) -Prevention / improvement function of fatty liver comprising conjugated polyunsaturated fatty acids having a structure (hereinafter abbreviated as conjugated triene structure), salts thereof, and ester derivatives thereof And a food and medicine using the composition.

[0002]

2. Description of the Related Art Fatty liver refers to a state where fat is excessively accumulated in the liver (hepatocytes).
Symptoms such as weight loss and fatigue. The mechanism of the development of fatty liver is still unknown, but according to previous studies, it is thought that: That is, the liver plays an important role in the metabolism and transfer of fat, and in a normal state, the balance of fat in the liver is kept in a certain equilibrium state. Neutral fat in the liver is derived from fatty acids in chylomicron derived from diet, free fatty acids mobilized from peripheral adipose tissue, and fatty acids newly synthesized in the liver. Some of the newly synthesized or transferred fatty acids to the liver in this way are oxidatively degraded in the liver, but some are esterified by the liver microsomes to become neutral fats, which bind to proteins and become lipophilic. Secreted into the bloodstream in the form of proteins. Hepatic triglyceride is maintained in an equilibrium state with relatively fast metabolism and turnover, but disrupts this equilibrium, ie, changes that cause an imbalance between the production and utilization of triglyceride in the liver. When it occurs, fatty liver develops. The causes of fatty liver are, in principle, (1) increased lipogenesis in the liver,
(2) decrease in fatty acid oxidation in the liver, (3) increase in mobilization of fat from the stored fat to the liver, (4) decrease in the movement of fat from the liver to the periphery, , Severe anemia, lack of oxygen due to circulatory disorders, endocrine disorders such as Graves' disease, metabolic diseases due to pediatric constitution, pancreatic disease, malnutrition, foreign toxins or drugs due to alcohol, phosphorus, mushroom venom, etc., chronic infections Numerous causes are listed, such as endogenous toxicants, fat and carbohydrate diet, and small intestinal bypass surgery. Fatty liver is considered to be a cause of serious diseases such as chronic hepatitis and cirrhosis, and treatment and prevention thereof are important issues. Concerning the method of preventing and treating fatty liver, conjugated dienlinoleic acid (conj
A hepatic fat accumulation-inhibiting composition comprising an effective amount of ugated linoleic acid (hereinafter referred to as "CLA") together with a pharmaceutical carrier or a food carrier (JP-A-11-79).
987), about 2 phospholipids in fats and oils containing polyunsaturated fatty acids
An oil or fat composition containing 5 to about 70% by weight of egg yolk lipid (JP-A-10-237480), at least one of amino acids having a glucagon secretion action, at least one of xanthine derivatives, and at least one of thiamine compounds. Composition containing one kind
-237480), a crude soybean lecithin fraction having a liver neutral fat synthesis inhibitory action obtained by fractionating crude soybean lecithin produced in the step of producing fats and oils from soybeans with an organic solvent, an adsorbent, an ion exchange resin and the like. Metabolism, the crude soybean lecithin fraction is blended with known raw materials, and the lipid metabolism containing food or drink, animal feed or medicine (Japanese Patent Application Laid-Open No. Hei 10-84879), an organic solvent or water extract of Kevlar pedra as an active ingredient Improving agent and liver injury suppressing agent (Japanese Patent Laid-Open No. 9-241)
176), a lipid increase inhibitor containing xyloglucan as an active ingredient (Japanese Patent Application Laid-Open No. 9-224608), a composition which is separated from buckwheat flour in a liquid layer in a mixture of buckwheat flour and water (Japanese Patent Application Laid-Open No. 9-183735), Curcuma (Curcum)
a xanthorrhiza Roxb. ), A lipid metabolism-improving agent containing as an active ingredient α-curcumene which is a bisabolane-type sesquiterpenoid (JP-A-7-149628), tristearin, 1-stearyl dipalmitin, 2-stearyl dipalmitin Fatty liver inhibitor comprising one or more triglycerides selected from, 1-palmitostearin and 2-palmitostearin as active ingredients (JP-A-6-2
79278), a hepatic function improving agent containing docosahexaenoic acid (referred to as DHA) as an active ingredient (JP-A-5-33915).
4) a hemicellulose obtained by removing starch, proteins and the like from corn bran and extracting the remainder with alkali, and / or a hemicellulose obtained by further treating the hemicellulose with xylanase, Techniques such as an alcoholic fatty liver inhibitor (JP-A-5-43470) to be contained as an active ingredient are known, but no effective preventive or therapeutic method has yet been established, and it is safer and more effective. The development of new active ingredients and compositions containing them, as well as new foods and pharmaceuticals utilizing them, has been awaited.

[0003]

SUMMARY OF THE INVENTION An object of the present invention is to provide a novel composition having a function of preventing and improving fatty liver, and a food and a medicine using the same.

[0004]

Means for Solving the Problems The present inventors have already found that conjugated polyunsaturated fatty acids having a conjugated triene structure are peroxisome activator-responsive receptors (PPARs), which are important regulators of fat metabolism. proliferator-acti
The present inventors have found that a triglyceride derivative exerts a visceral fat accumulation inhibitory action and an accumulated fat reduction promoting action in experimental animals in a laboratory animal, and applied for a patent (Japanese Patent Application No. 11-108588). Then, as a result of further studying the use of the conjugated polyunsaturated fatty acid having the conjugated triene structure, its salt, and its ester derivative, it was found that the component not only prevents fatty liver but also improves it, and further studies were conducted. As a result, the present invention has been completed.

That is, the first aspect of the present invention is that a conjugated triene structure (-(CH = CH-CH = CH-CH = CH)) is contained in a molecule.
-Prevention / improvement function of fatty liver, comprising one or more selected from the group consisting of a conjugated polyunsaturated fatty acid having-), a salt of the conjugated polyunsaturated fatty acid, and an ester derivative of the conjugated polyunsaturated fatty acid. A composition having the formula: In a preferred embodiment, (1) the conjugated polyunsaturated fatty acid is at least one selected from the group consisting of punicic acid, calendic acid, jacaric acid, α-eleostearic acid, β-eleostearic acid, and catalpic acid (2) The composition according to the above, wherein the ester derivative of the conjugated highly unsaturated fatty acid is an ethyl ester or a glycerol ester derivative, (3)
Roots, stems, leaves of plants belonging to the family Pomegranate, Agriculture
The above-mentioned composition comprising at least one selected from the group consisting of flowers or seeds, extracts thereof, or processed products thereof; (4) the plant extract is pomegranate seed oil, calendula seed oil, Russell seed oil, catalpa seed oil, American cattle seed oil, bitter gourd seed oil,
Balsam Apple Seed Oil, Snake Guard Seed Oil, Chikarasuuri Seed Oil, Pumpkin Seed Oil, Aburagiri Seed Oil,
Alternatively, the present invention relates to the composition described above, which is at least one member selected from the group consisting of cherry seed oil.

A second aspect of the present invention relates to a food having the function of preventing and improving fatty liver comprising the above-described composition, and a third aspect of the present invention relates to a food having a fatty liver preventing and improving function comprising the above-described composition. The present invention relates to a drug having an improving function.

[0007]

BEST MODE FOR CARRYING OUT THE INVENTION Hereinafter, the composition of the present invention will be described in detail.

[0008] The composition of the present invention comprises at least one of a conjugated polyunsaturated fatty acid having a conjugated triene structure in the molecule, a salt thereof, and an ester derivative thereof,
In addition, it has a function of preventing and improving fatty liver. As conjugated polyunsaturated fatty acids having a conjugated triene structure in the molecule,
Those having a conjugated triene structure in the molecule, and food, nutritional, physiological, pharmaceutically acceptable, if carbon number, the number of other unsaturated bonds and It is not limited by the position, the presence or absence of a substituent, and the like. Preferably, a conjugated polyunsaturated fatty acid having 10 to 22 carbon atoms and a degree of unsaturation of 3 to 6 is used. preferable. A specific example is punicic acid
(punicicacid) (18: 3, 9c, 11t, 13c),
Calendic acid (18: 3,8t,
10t, 12c), jalcaric acid (18: 3,8)
c, 10t, 12c), α-eleostearic acid (α-ele
ostealic acid) (18: 3, 9c, 11t, 13t),
β-eleostealic acid (1
8: 3, 9 t, 11 t, 13 t), catalpic acid (cata
lpic acid) (18: 3, 9t, 11t, 13c), kamlolenic acid (18OH, 9c,
11t, 13t) and other conjugated octadecatrienoic acid, eicosatetraenoic acid and the like. Punicic acid and α-eleostearic acid are most preferred in terms of stability and economy.

[0009] The conjugated polyunsaturated fatty acid of the present invention may be in the form of a salt or an ester derivative. The salt is not particularly limited as long as it is food, nutritional, or pharmacologically acceptable. Sodium salts, metal salts such as calcium salts, ammonium salts, methylamine, ethylamine,
Salts with organic bases such as diethylamine, triethylamine, pyrrolidine, piperidine, morpholine, hexamethyleneimine, aniline and pyridine, and salts with amino acids such as arginine, glutamic acid and ornithine are included. In addition, as the ester derivative, any food, nutritional, or pharmacologically acceptable one can be selected, but ethyl ester, butyl ester, propyl ester, and glycerol ester are preferable. More preferred are ethyl ester and glycerol ester. The glycerol ester derivative may be in any form of monoglyceride, diglyceride, and triglyceride, but diglyceride and triglyceride are preferred in view of physical properties as a food or pharmaceutical composition, and triglyceride is most preferred. In these diglycerides and triglycerides, the position at which the conjugated polyunsaturated fatty acid is esterified may be selected according to the purpose, and is not particularly limited. Specific conjugated highly unsaturated fatty acid ester derivatives include ethyl punicate, ethyl calendate, ethyl jarcaricate, ethyl α-eleostearate, ethyl β-eleostearate, ethyl catalpinate, ethyl parinarate, Butyl punicate, α-butyl eleostearate, propyl punicate, propyl α-eleostearate, 1-punicyl-sn-glycerol (1-punicyl-sn-glycero)
l), 2-Punisyl-sn-glycerol (2-punicy
l-sn-glycerol), 1,2-dipunisil-sn-glycerol (1,2-dipunicyl-sn-glycerol), 1,3-
Zipniseal-sn-glycerol (1,3-dipunicyl
-sn-glycerol), 1,2,3-trypnicile -sn-
Glycerol (1,2,3-tripunicyl-sn-glycero
l), 1-α-eleostearyl-sn-glycerol (1-α-ereostearyl-sn-glycerol), 2-α-eleostearyl-sn-glycerol (2-α-ereosteary)
l-sn-glycerol), 1,2-diα-eleostearyl-sn-glycerol (1,2-diα-ereostearyl-sn-g)
lycerol), 1,3-diα-eleostaryl-sn
Glycerol (1,3-diα-ereostearyl-sn-glyce
rol) 1,2,3-tri-α-eleostaryl-sn
Glycerol (1,2,3-triα-ereostearyl-sn-gl
ycerol) and the like. The conjugated polyunsaturated fatty acids having a conjugated triene structure of the present invention, salts thereof, and ester derivatives thereof are those produced synthetically using chemical methods or enzymes, those extracted from natural animals and plants, Although various forms such as those obtained by chemically changing animals and plants are conceivable, considering the use as foods or pharmaceutical compositions, natural plants, animals, those prepared from marine products are preferable, Furthermore, from the aspect of securing quantity,
Stems, leaves, flowers, seeds and the like are more preferred. Examples of these plants include the pomegranate (Punicaceae),
ae (Asteraceae)), Euphordiacea (Euphordiacea)
e), Curvaceae (Cucuritaceae);
noniaceae), roots of plants belonging to the family Rosaeceae,
Examples include stems, leaves, flowers, or seeds. Easy to obtain quantitatively, the roots, stems,
Leaves, flowers or their seeds are more preferred. Some of these plants can be crushed, extracted and processed for use.

The method of crushing, extracting and processing the plant is as follows:
Any method that does not adversely affect the effects of preventing and improving fatty liver and the physical properties and flavor of the composition can be selected from general methods. For example, as a method of pulverizing, there are a method using a mortar, a blender, a mill, a homogenizer, a roller, a pressing machine, and the like, and a method of applying an impact in a frozen state. In addition, as a method of extracting, the pulverized seeds and the like are n
-There is a method of extracting using an organic solvent such as hexane or acetone, or a method of performing solid-liquid separation using a pressing machine or the like.

In the present invention, among the extracts obtained from plants, seed oil extracted from seeds is preferred. Specific examples of preferred plant seed oils include pomegranate seed oil, calendula seed oil, rosewood seed oil, catalpa seed oil, American cattle seed oil, bitter gourd seed oil,
Balsam Apple Seed Oil, Snake Guard Seed Oil, Chikarasuuri Seed Oil, Pumpkin Seed Oil, Aburagiri Seed Oil,
Or cherry seed oil and the like. Of these, pomegranate seed oil, bitter gourd seed oil, balsam apple seed oil, snake guard seed oil, abragiri, based on the content of conjugated highly unsaturated fatty acids, their salts and ester derivatives in the seed. Seed oil is preferred, because of its availability, pomegranate seed oil,
Bittern seed oil is most preferred.

[0012] The composition of the present invention is not particularly limited by the purity of the active ingredient as long as it exhibits the effect of preventing and improving fatty liver. For example, the active ingredient may be purified from natural raw materials to high purity by adsorption chromatography, partition chromatography, ion exchange chromatography, molecular sieve chromatography, fractional extraction with an organic solvent, fractional crystallization, molecular distillation, etc. good.

The content of the conjugated polyunsaturated fatty acid having a conjugated triene structure, its salt, or its ester derivative in the composition of the present invention is not particularly limited, but is preferably 1%.
% Or more. If it is less than 1%, the effect of preventing and improving fatty liver may not be observed. The composition of the present invention can be used as it is or further processed into a food or pharmaceutical. For example, fatty acids or esters thereof may be obtained from vegetable seed oil. When a fatty acid is obtained, the above animal and vegetable fats and oils can be purified by a common method such as fractional extraction, column chromatography or the like after hydrolysis with alkali or lipase. The ester derivative of the conjugated polyunsaturated fatty acid in the present invention is not particularly limited by its production method, for example, a direct esterification method of synthesizing the fatty acid with ethyl alcohol, alcohol such as glycerol by a dehydration reaction, Transesterification method of synthesizing new ester by reaction of alcohol or ester with fatty acid or ester and ester, method of synthesizing from fatty acid chloride and alcohol, method of reacting epoxy compound with fatty acid, reaction of olefin with fatty acid It can be prepared by a general method such as a method of causing the compound to be prepared.

Foods containing the composition of the present invention include:
Bakery products of breads, processed foods of soybeans such as cooked rice, noodles and tofu, processed foods of fish and meat such as sausage and ham, cakes, cookies, buns, rice crackers, ice cream, pudding, sweets such as yokan, candy, chocolate, Dairy products such as butter, yogurt, cheese, etc., processed fats and oils foods such as margarine and shortening, seasonings such as mayonnaise, dressing, soy sauce, miso and sauces,
Beverages such as coffee, black tea, green tea, oolong tea, sports drinks, konjac, pickles, and the like.
The addition amount of the composition of the present invention in these foods is appropriately selected depending on the content of the conjugated polyunsaturated fatty acid having a conjugated triene structure, its salt, its ester derivative, and the purpose contained in the composition. It is preferable to add conjugated polyunsaturated fatty acid having a conjugated triene structure, a salt thereof, or an ester derivative thereof in an amount of 1% by weight or more.

The food containing the oil / fat composition of the present invention can contain various carriers and additives in addition to the conjugated polyunsaturated fatty acid having a conjugated triene structure of the present invention, a salt thereof, and an ester derivative thereof. Carriers and additives used are
Any composition may be used as long as it does not adversely affect the function of the composition of the present invention for preventing or improving fatty liver. Specific examples of such carriers include various carrier carriers, extenders,
Diluents, extenders, dispersants, excipients such as lactose, binders such as hydroxypropylcellulose (HPC), polyvinylpyrrolidone (PVP), solvents such as water, ethanol, vegetable oils, solubilizers, buffers such as baking soda. Agents, dissolution promoters, gelling agents such as sodium CMC, HPMC, agar and gelatin, and suspending agents such as sodium CMC and sodium alginate. Specific examples of additives include seasonings for improving edibility and palatability such as glutamine soda and inosinic acid, flavors such as vanilla, mint, rosemary, linalool, and natural flavors, vitamin A, and vitamin B1. Vitamins such as vitamin B2, vitamin B6, vitamin C, vitamin E, pantothenic acid, nicotinic acid, organic acids such as citric acid, malic acid, fumaric acid, malonic acid, succinic acid, tartaric acid, lactic acid, coloring agents, moisture Inhibitor,
Fibers, electrolytes, minerals, nutrients, antioxidants, preservatives, fragrances, humectants, tea extracts, coffee extracts, cocoa extracts, orange, grape, apple, peach, pineapple, pear, plum, cherry, papaya And natural plant extracts such as fruit extracts such as tomato, melon, strawberry, raspberry and the like.

When the oil / fat composition of the present invention is used as an active ingredient of a drug, it is used as it is or in a pharmaceutically acceptable non-toxic and inert carrier. In this case, the content of the conjugated polyunsaturated fatty acid having a conjugated triene structure, a salt thereof, and an ester derivative thereof is preferably 1% or more. As the carrier, solid, semi-solid, liquid pharmaceutical preparations can be used in the usual production of the carrier, and is not particularly limited, excipients such as glucose and lactose, starch, carboxymethylcellulose calcium Disintegrating agents such as (CMC-Ca), hydroxypropylcellulose (HPC), polyvinylpyrrolidone (PV
A binder such as P), a lubricant such as talc or magnesium stearate, a pH regulator such as baking soda, a stabilizer, a diluent, a coloring matter, and other auxiliaries for formulation can be used. The medicament of the present invention includes tablets, capsules, granules, powders, powders, dragees, suspensions, solutions, syrups, drops,
It can be used as an oral preparation such as sublingual tablets and emulsifiers, or as a parenteral preparation such as injections and suppositories. If long-term administration is required, oral administration is preferred.

The composition of the present invention and a food containing the composition,
Drugs include fatty liver due to alcohol intake, fatty liver due to excessive intake of energy, fatty liver due to reduced lipolysis in the liver, fatty liver due to increased lipogenesis in the liver, and fatty liver due to increased absorption of fat in the small intestine. It can be used as a material for health maintenance and health promotion foods because it can be expected to prevent and improve fatty liver caused by various factors. Usually, when the liver function is reduced by fatty liver, the physical strength is significantly reduced. Therefore, its prevention
Since the improvement leads to maintenance, enhancement and recovery of physical strength, the food composition of the present invention can be used as a health food composition for maintenance, enhancement and recovery of physical strength.

[0018]

The present invention will be described in more detail with reference to the following examples, but the present invention is not limited to these examples. (Example 1) Preparation of plant seed oil Dried pomegranate seeds, calendula seeds, bitter melon seeds, catalpa seeds, snake guard seeds, balsam apple seeds or western cherry seeds were oiled using a small oil mill (uniaxial screw expeller). 1
Centrifugation at 000 G for 30 minutes yielded clear pomegranate seed oil, calendula seed oil, bitter melon seed oil, catalpa seed oil, balsam apple seed oil, snake guard seed oil, and western cherry seed oil.

As a result of analyzing the fatty acid composition of each of the obtained fats and oils, pomegranate seed oil contained 71.6% of punicic acid, calendula seed oil contained 33.4% of calendic acid, and bitter gourd seed oil contained α-eleostearic acid. 46.5%, Catalpinic acid is 31.3% for catalpa seed oil, Punicic acid is 48.5% for snake guard seed oil, Punicic acid is 68.0% for Balsam apple seed oil, Western cherry seed oil is α -It was confirmed that eleostearic acid contained 11.0%. (Example 2) Fatty liver preventing effect of plant seed oil The fatty liver preventing effect of each plant seed oil obtained in Example 1 was evaluated using mice. Ten-week-old female C57BL / 6J mice (Crj: CD-1 (ICR), manufactured by Charles River Japan Co., Ltd.) were divided into 5 groups / group, and control group 1 had high fat and high composition as shown in Table 1. In a sugar-fed purified feed (manufactured by Oriental Yeast Co., Ltd.), a control group 2 was prepared by adding 8% soybean oil as a fat to a standard compound feed for growth period (AIN-93G: manufactured by Oriental Yeast Co., Ltd.) from which fat was removed. The test group was bred using a feed in which 8% of the lard in the fat of the high-fat / high-sugar-purified purified feed was replaced with test oil and fat. Pomegranate seed oil prepared in 1, test group 2 is calendula seed oil, test group 3 is catalpa seed oil, test group 4 is snake guard seed oil, test group 5 is balsam apple seed oil, test group 6 is western cherry seed oil Were tested using six seed oils of The rats were bred for 4 weeks on a test feed or a control feed, fasted for about 16 hours from the last day, exsanguinated under ether anesthesia, and excised from the liver.The liver was fixed with formalin, paraffin sections were prepared by a conventional method, and hematoxylin and The cells were stained with eosin, and the pathological tissue was searched with an optical microscope.The degree of steatosis in the liver was classified into five grades, and the results were evaluated based on the number of individuals for each grade, and the results are shown in Table 2. In the high sugar diet breeding (control group 1), an image of fat accumulation and liver in the liver was observed, and such an image was not observed in the normal diet (control group 2). In each case, an image in which accumulation of fat was suppressed was observed.

[0020]

[Table 1]

[0021]

[Table 2] (Example 3) Evaluation of fatty liver improving effect of plant seed oil The fatty liver improving effect of the plant seed oil prepared in Example 1 was evaluated using mice. 10-week-old female C57BL / 6J
A mouse (Crj: CD-1 (ICR), manufactured by Charles River Japan Co., Ltd.) was prepared from a high-fat, high-sugar fractionated purified feed (manufactured by Oriental Yeast Co., Ltd.) having a composition shown in Table 2 and contained in soybean oil (15
%) Was fed for 4 weeks on a feed replaced with beef tallow to obtain a fatty liver condition. Thereafter, the animals were randomized using body weight as an index and divided into 5 animals / group. One group was fasted for 16 hours, dissected, and the degree of fatty liver in the liver was evaluated in the same manner as in Example 2 (control group 3). The remaining groups were further fed for 4 weeks on the following diet. The control group 4 was a standard mixed feed for growth period (AIN-
93G: manufactured by Oriental Yeast Co., Ltd.) with 10% soybean oil as fat. The test group was bred on a diet prepared by adding soybean oil and test oil and fat to the same standard diet as the control group at a total fat content of 10%. The test oil was 8% pomegranate seed oil in test group 7, 2% pomegranate seed oil in test group 8, 8% catalpa seed oil in test group 9, 8% snake guard seed oil in test group 10, and balsam in test group 11. 8% of apple seed oil was used. After fasting for about 16 hours from the last day of breeding, the animals were exsanguinated under ether anesthesia and the liver was removed. In the same manner as in Example 1, the degree of liver fatty degeneration was histopathologically classified into five grades, and the number of individuals per grade was evaluated. Table 3 shows the results. In the group to which the composition of the present invention was added, it was revealed that the degree of liver fatty degeneration was remarkably improved as compared with the control group 4.

[0022]

[Table 3] (Example 4) Fatty liver improving effect of crushed plant seeds The fatty liver model mice prepared in the same manner as in Example 2 were divided into 5 mice / group, and the control group was for growth period to which 10% soybean oil was added. They were bred on a standard combination feed (AIN-93G: manufactured by Oriental Yeast Co., Ltd.) (control group 5). In Test Group 12, a powder prepared by pulverizing dried pomegranate seeds in a mortar was added to the control group feed at 20% (% by weight) to prepare a feed. After breeding for 4 weeks, the degree of liver fatty degeneration was evaluated in the same manner as in Example 2.
The results are shown in Table 4. There was no significant increase in body weight or feed intake between the two groups. In the group reared on the diet to which pomegranate seed powder was added, a clear improvement in fatty liver was observed.

[0023]

[Table 4] (Example 5) Preparation of capsule for oral use Pomegranate seed oil, calendula seed oil, bitter melon seed oil, catalpa seed oil, balsam apple seed oil, snake guard seed oil, western cherry, obtained in the same manner as in Example 1. Seed oil 40mg, lactose 200mg, starch 70m
g, polyvinylpyrrolidone 5, crystalline cellulose 35 mg
After mixing, the mixture was filled into a # 3 gelatin capsule, and the surface was coated with gelatin to prepare an oral capsule. (Example 6) Preparation of oral tablets Pomegranate seed oil, calendula seed oil, bitter melon seed oil, catalpa seed oil, balsam apple seed oil, snake guard seed oil, western cherry seed oil obtained by the same method as in Example 1 5 g, lactose 70 g, and corn starch 30 g are uniformly mixed, and 25 ml of a 10% hydroxypropylcellulose solution is added thereto, followed by stirring and granulation. After drying, sieving, magnesium stearate 2g, talc 2g
Can be added and mixed to produce tablets using a rotary tableting machine. (Example 7) Preparation of conjugated trienoic acid triglyceride-containing emulsifier Intralipi (Intralipi, manufactured by Baxter Co.)
d) 95 parts of pomegranate seed oil obtained as in Example 1,
Calendula seed oil, bitter melon seed oil, catalpa seed oil,
Balsam apple seed oil, snake guard seed oil, and 5 parts of western cherry seed oil were added and emulsified to obtain an emulsifier containing conjugated trienoic acid triglyceride.

[0024]

EFFECTS OF THE INVENTION Foods and pharmaceutical compositions containing conjugated polyunsaturated fatty acids having a conjugated triene structure, salts thereof, and ester derivatives thereof as active ingredients and exhibiting a preventive / ameliorating effect on fatty liver are provided. It can be used as a food material for improving health foods, health drinks, nutritional tonics, and maintaining physical strength. Further, it can be used as a pharmaceutical composition for preventing and / or improving fatty liver.

──────────────────────────────────────────────────の Continued on the front page (51) Int.Cl. ⁷ Identification code FI Theme coat ゛ (Reference) A61K 31/232 A61K 35/78 C 4H059 35/78 T S L H A61P 1/16 A61P 1/16 3 / 00 3/00 C11B 1/06 C11B 1/06 1/10 1/10 3/00 3/00 7/00 7/00 C11C 3/00 C11C 3/00 A23D 9/00 516 F-term (reference) 2B150 AA10 AB20 DA37 DD31 DD57 4B018 LB08 MD10 MD15 MD48 MD52 MD53 ME02 ME14 4B026 DC05 DG01 4C088 AB12 AB19 AB26 AB46 AB51 AC03 AC04 AC05 AC11 BA08 BA32 CA02 CA03 NA14 ZA75 ZC33 4C206 AA01 AA02 DA05 DB09 DB41 DB43 DB47 MA03 MA04 Z0433 BC03 BC44 CA04 CA06 CA09 CA11 CA18 CA24 EA21

Claims (7)

[Claims] 1. A conjugated triene structure (-(CH =
Containing at least one selected from the group consisting of conjugated highly unsaturated fatty acids having CH-CH = CH-CH = CH)-), salts of the conjugated highly unsaturated fatty acids, and ester derivatives of the conjugated highly unsaturated fatty acids. A composition having the function of preventing or improving fatty liver. 2. The conjugated polyunsaturated fatty acid is at least one selected from the group consisting of punicic acid, calendic acid, jacaric acid, α-eleostearic acid, β-eleostearic acid, and catalpic acid. The composition according to claim 1, characterized in that: 3. The composition according to claim 1, wherein the ester derivative of the conjugated polyunsaturated fatty acid is an ethyl ester or a glycerol ester derivative. 4. A pomegranate family, a pterodaceae family, a pomegranate family,
At least one member selected from the group consisting of roots, stems, leaves, flowers, or seeds of plants belonging to the family Rubiaceae, Rubiaceae, or Rosaceae, their extracts, or their processed products
A composition according to any of the preceding claims, comprising a seed. 5. The plant extract may be a pomegranate seed oil, a calendula seed oil, a rose quail seed oil, a catalpa seed oil, an American catalpa seed oil, a bitter gourd seed oil, a balsam apple seed oil, a snake guard seed oil, a chili cucumber seed. At least one selected from the group consisting of oil, pumpkin seed oil, ragweed seed oil, or cherry seed oil
A composition according to any of the preceding claims, which is a seed. 6. A food having the function of preventing and improving fatty liver, comprising the composition according to any one of claims 1 to 5. 7. A medicament comprising the composition according to claim 1 and having a function of preventing and improving fatty liver.